Helicos BioSciences (FRA:HB4) Beta : N/A (As of Jun. 16, 2024)

View and export this data going back to . Start your Free Trial

What is Helicos BioSciences Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-16), Helicos BioSciences's Beta is Not available.

Helicos BioSciences Beta Historical Data

The historical data trend for Helicos BioSciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helicos BioSciences Beta Chart

Helicos BioSciences Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Beta

Get a 7-Day Free Trial

3.49

3.12

4.58

Helicos BioSciences Semi-Annual Data
	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11
Beta	Get a 7-Day Free Trial			-	-	3.49	3.12	4.58

Competitive Comparison of Helicos BioSciences's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Helicos BioSciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helicos BioSciences's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Helicos BioSciences's Beta distribution charts can be found below:

* The bar in red indicates where Helicos BioSciences's Beta falls into.

Helicos BioSciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Helicos BioSciences (FRA:HB4) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Helicos BioSciences Beta Related Terms

Thank you for viewing the detailed overview of Helicos BioSciences's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Helicos BioSciences (FRA:HB4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Helicos BioSciences Corp (FRA:HB4) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Helicos BioSciences Corp is incorporated in the state of Delaware and was incorporated on May 9, 2003. It is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The Company's products are based on its proprietary True Single Molecule Sequencing (tSMS) technology which enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. The Company's Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies. The Company is subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of its operations and markets.

Helicos BioSciences (FRA:HB4) Headlines

No Headlines